EMA Validates Varegacestat Application for Desmoid Tumors
The EMA has started reviewing Immunome's application for varegacestat to treat desmoid tumors in adults. The application is supported by phase 3 RINGSIDE trial data showing an 84% reduction in disease progression risk. The FDA has also accepted Immunome's application with a target action date of April 28, 2027.
How this was made

The 30-second read
Why it matters
Regulatory validation moves the drug closer to market, potentially unlocking revenue and enhancing the company's valuation.
Market read
The EMA step is a key milestone that could drive share price appreciation ahead of a US FDA decision.
What to watch
Manufacturing scale‑up, pricing negotiations, and competition from other Notch pathway drugs could limit upside.
Background
Immunome's varegacestat showed strong Phase 3 efficacy in desmoid tumors, with 84% risk reduction and 55.7% response rate.
Ticker impact
EMA validated Immunome's marketing authorization application for varegacestat, clearing the way for a centralized review.
likely upward pressure as investors price in potential EMA approval and subsequent US filing progress
Regulatory validation is a material catalyst for a biotech with a late‑stage trial readout; market typically reacts positively to EMA acceptance.
Market effects
Strengthens the broader oncology/rare‑disease biotech sector by showing regulatory pathways for gamma‑secretase inhibitors.
European biotech stocks may see modest gains on the back of EMA activity.
Potentially influences global investors tracking rare‑tumor therapeutics.
Counterpoint
If EMA approval stalls or requires additional data, the stock could face disappointment despite the validation.
Key entities
- companyImmunome, Inc.
Biotech developer of varegacestat.
- regulatorEuropean Medicines Agency (EMA)
Validated the marketing authorization application.
